Biotech and Pharmaceuticals Medicine

  • Cubist advances Sivextro

    Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.

  • VA Crisis: Keeping whistleblowers safe

    An inside look at how management manipulated patient wait times at the Department of Veterans Affairs, with CNBC's Dina Gusovsky.

  • Researchers have discovered that an FDA-approved arthritis drug may hold the secret to curing hairlessness.

  • Solution to backlog in legal system

    Medical malpractice insurance costs are soaring. Philip Howard, author of "The Rule of Nobody," provides insight to the consequences of increasing malpractice lawsuits, and how to reduce them.

  • Ten milligram tablets of the hyperactivity drug, Adderall, made by Shire Plc.

    Shire has hired investment bank Citi as an adviser following a wave of deals in the healthcare sector.

  • The New York Times building in New York City.

    New York Times Executive Editor Dean Baquet disclosed that he had a malignant tumor on his kidney that was removed over the weekend.

  • The diabetes battleground

    CNBC's Meg Tirrell takes a look at the companies behind the fight against diabetes.

  • Cool pharma tech

    CNBC's Meg Tirrell reports which pharmaceutical stocks are ready for the future of medicine, including Covidien's swallowable pill-size camera.

  • Revolutionary genomic testing

    David Neeleman, JetBlue founder & AZUL Airlines founder & CEO, and Dr. Florence Comite, Precision Health Care, explain "genetically driven health care," a personalized approach that uses your genetic code to determine the best medications for you.

  • Rethinking health care

    Why does the U.S. spend so much money on health care? Daniel Kraft, Exponential Medicine executive director, says the U.S. spends a lot of money on "sick" care, not health care, and provides insight to new technology developments in the industry.

  • Marilyn Tavenner

    Medicare Advantage plans are facing audits that could order them to repay tens of millions of dollars for billing errors.

  • The Center for Public Integrity found missed chances to corral tens of billions of dollars in Medicare Advantage billing errors.

  • Senate fix for VA

    The Senate has reached a bipartisan deal that would give some veterans a chance to seek out their own care in the private market. Dan Caldwell, Concerned Veterans for America, explains what type of culture at the VA led to this deal.

  • Benefits of booking with ZocDoc

    ZocDoc is a medical care scheduling service allowing users to find and book a doctor online. Cyrus Massoumi, ZocDoc CEO, weighs in on Apple's HealthKit and explains how the free search facility functions.

  • In 2012, hospitals charged more for every one of 98 common ailments that could be compared to the previous year.

  • Bristol-Myers' pioneering melanoma research

    CNBC's Meg Tirrell and Dr. Michael Giordano, senior vice president of oncology and immunosciences development at Bristol-Myers Squibb, discusses advances to cure melanoma and cancer research costs.

  • Patients can try new once-a-day tablets that dissolve quickly under the tongue and raise tolerance to grass or ragweed pollen, much like the shots.

  • VA system currently unfixable: Schnipper

    President Obama announced the resignation of Veterans Affairs Secretary Eric Shinseki. Eric Schnipper, NRAD Medical Associates partner, addresses the major problems with the VA system.

  • Immunotherapies hit ASCO

    This year's biggest cancer conference begins tomorrow. CNBC's Meg Tirrell reports why immunotherapy drugs will be a key theme with drug makers at ASCO.

  • War on cancer

    The big topic at this year's cancer care conference ASCO will be immunotherapy drugs. CNBC's Meg Tirrell explains how these drugs work.